Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emphasys Medical Inc.

This article was originally published in Start Up

Executive Summary

In June 2000 The Foundry founded Emphasys Medical to develop a minimally invasive alternative to lung volume reduction surgery. As such, it became part of the avant garde in interventional pulmonology, a small group that also includes Spiration, Broncus Technologies, and Pulmonx.

You may also be interested in...



Rox Gets Blood Pumping in COPD

Rox Medical is taking an unusual approach to treating COPD by introducing a vascular device that increases oxygen delivery to tissue and cardiac output. The potential has investors' hearts racing as well.

Pulmonary Device Companies Take It To The Streets - In Europe

For the past decade, venture capitalists have invested in companies that are developing new technologies to treat late-stage chronic obstructive pulmonary disorders.Despite hundreds of millions in venture capital dollars, the companies have made little progress in bringing these products to market in the US. But this band of start-ups is taking the fight to the streets - of Europe.

Tighter FDA Review Squeezing Device VCs

For over three decades, medical device investors have accepted the Food and Drug Administration's crucial role as traffic cop for their start-ups. Yes, the agency could be tough, but a green light opened a lucrative road for device companies. But venture capitalists are increasingly worried that tighter controls on regulation could endanger innovation.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT037303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel